Dec 14, 2020
Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis.
Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis
Learning Objectives: After completing this educational activity, you should be better able to:
- Describe the clinical presentation of psychosis in dementia
- Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia
Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.
Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.
Peer Review: The content was peer-reviewed by a PhD specializing in neurodegenerative diseases to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.
Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.
Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY
Upstate Medical University, Syracuse, NY
Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck,
Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi
Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck,
Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda,
Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive,
Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research,
Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis,
Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva
Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor,
Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen,
Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva,
Tris
Interviewee
Laxman Bhagwan Bahroo, DO
Associate Professor and Residency Program Director, Department
of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown
University Hospital Pasquerilla Healthcare Center, Washington,
DC
Consultant/Advisor: AbbVie, Acadia, Acorda, Allergan, Amneal,
Neurocrine, Revance, Sunovion, US World Meds
Speakers Bureau: AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal,
Ipsen, Neurocrine, Sunovion, UCB, US World Meds
Pre-Interview Author
Sabrina K. Bradbury-Segal, PhD
Medical Writer, Neuroscience Education Institute, Carlsbad,
CA
No financial relationships to disclose.
The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture
Support: This activity is supported by an unrestricted educational grant from Acadia Pharmaceuticals.
Released: December 14, 2020 CME credit expires: December 14, 2023